ADVERTISEMENT

Can Immunotherapy Conquer Triple-Negative Breast Cancer?

Triple-negative breast cancer (TNBC) is a subtype of breast cancer, the most common cancer in women. TNBC is clinically negative for expression of the estrogen receptor (ER) and progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2). This disease is highly aggressive and lacks effective targeted therapies. Currently, chemotherapy is the only therapeutic option in the adjuvant or metastatic setting for TNBC.

Although numerous targeted therapies for TNBC have been investigated, the clinical trial efficacies of these therapies are unsatisfactory or remain unclear. Recently, cancer immunotherapy has achieved successes in treating a variety of cancers including refractory malignancies such as metastatic melanoma, advanced lung cancer, and Hodgkin’s lymphoma. Thus, immunotherapy for TNBC is being considered as a viable clinical objective, especially considering the very limited therapeutic options currently available for TNBC.

ADVERTISEMENT

One of the most exciting advances in cancer immunotherapy is the blockade of immune checkpoint molecules such as cytotoxic T-lymphocyte-associated protein 4 (CTLA4), programmed cell death protein 1 (PD1), and programmed cell death 1 ligand (PD-L1). Another notable advance in cancer immunotherapy is the chimeric antigen receptor (CAR) T cell therapy. This method has been successfully used to treat refractory leukemia and lymphoma. However, currently, these immunotherapeutic strategies only show beneficial effects in less than 20% of cancer patients. Hence, it is important to find molecular biomarkers that are useful for predicting responders to cancer immunotherapy. Researchers have discovered some such biomarkers, such as tumor mutation burden, neoantigen load, PD-L1 expression, and deficient DNA mismatch repair.

It should be noted that with the rapid advancement of the next-generation sequencing (NGS) technology, it is possible to discover the genomic features that are associated with the cancer immunotherapeutic responsiveness. For example, researchers have found that the tumor mutation load has a positive correlation with clinical response of cancer patients to CTLA4 or PD1 blockade. The high DNA mismatch repair deficiency correlates with active clinical response to cancer immunotherapy.

Immunotherapy has not been clinically used for breast cancer because compared to melanoma, lung cancer, renal cancer, lymphoma, bladder cancer, or head and neck cancer, breast cancer, in general, has weaker immunogenicity. However, researchers showed the existence of distinct immunogenic activity in breast cancer subtypes. Based on a couple of large-scale breast cancer genomics data, researchers performed a comprehensive and exhaustive analysis of various immunogenic signatures in breast cancer.

Strikingly, they found that all the immunogenic signatures showed a significantly stronger signal in TNBC compared to non-TNBC, demonstrating that TNBC has the strongest tumor immunity of all breast cancer subtypes. Particularly, the gene or genomic features such as PD-L1 expression, tumor mutation burden, and neoantigen load that are active signatures for cancer immunotherapeutic response, show significantly higher levels in TNBC than in non-TNBC, indicating that TNBC is the breast cancer subtype most propitious to immunotherapy.

ADVERTISEMENT

Another interesting finding is that most of the immunogenic signatures have a positive correlation with survival prognosis in TNBC. Finally, researchers showed that TNBC had significantly higher expression levels of most of the genes targeted by immunotherapy agents in clinical use or trials or in preclinical development than non-TNBC, indicating that these agents may be good candidates for clinical trials for TNBC immunotherapy.

In conclusion, these findings suggest that of the various breast cancer subtypes, TNBC likely exhibits the strongest immunogenicity, and warrant immunotherapeutic options for TNBC.

These findings are described in the article entitled A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer, recently published in the journal Translational OncologyThis work was conducted by Zhixian Liu, Mengyuan Li, Zehang Jiang and Xiaosheng Wang from China Pharmaceutical University.

Comments (2)

Comments

READ THIS NEXT

The Ambitious & Risky Race To Colonize Mars

Space exploration is the final frontier left to explore by humanity. In many science fiction novels, we have colonies from […]

How Human Skeletons Are Illuminating Europe’s Islamic Past

Bioarchaeology, a field that combines the methods of archaeology and biological/physical anthropology, uses archaeological human skeletal remains to better understand […]

Enormous Hidden Void Discovered Within The Great Pyramid Of Giza

The Great Pyramid of Giza is over 4500 years old, but secrets about it are still being discovered. Just recently […]

What Is Rose Quartz?

Rose quartz is a specific mineral variety of crystalline quartz that is characterized by its soft pinkish hue. The particular shade […]

Stimulation Of The Prefrontal Cortex Found To Reduce Violent Impulses

The prefrontal cortex is an area of the mammalian brain that covers part of the brain’s frontal lobe. The prefrontal […]

Improving Brain Function In Alzheimer’s Disease Patients Through A Bioresorbable Device

Nowadays, the association between engineering and biomedicine has increased, providing innumerable biomaterials for uncountable applications. And, why not consider these […]

DNA Combing Technology: A Simple But Useful Technique

DNA combing is a simple technique which can be used for visualization of single DNA molecules by following simple steps. […]

Science Trends is a popular source of science news and education around the world. We cover everything from solar power cell technology to climate change to cancer research. We help hundreds of thousands of people every month learn about the world we live in and the latest scientific breakthroughs. Want to know more?